Your browser doesn't support javascript.
loading
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.
Muchtar, Eli; Dispenzieri, Angela; Wisniowski, Brendan; Palladini, Giovanni; Milani, Paolo; Merlini, Giampaolo; Schönland, Stefan; Veelken, Kaya; Hegenbart, Ute; Geyer, Susan M; Kumar, Shaji K; Kastritis, Efstathios; Dimopoulos, Meletios A; Liedtke, Michaela; Witteles, Ronald; Sanchorawala, Vaishali; Szalat, Raphael; Landau, Heather; Petrlik, Erica; Lentzsch, Suzanne; Coltoff, Alexander; Bladé, Joan; Cibeira, Maria Teresa; Cohen, Oliver; Foard, Darren; Wechalekar, Ashutosh; Gertz, Morie A.
Afiliação
  • Muchtar E; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Wisniowski B; National Amyloidosis Centre, University College London, Royal Free Hospital Campus, London, United Kingdom.
  • Palladini G; Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Milani P; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Merlini G; Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Schönland S; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Veelken K; Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Hegenbart U; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Geyer SM; Medical Department V, Amyloidosis Center, University of Heidelberg, Heidelberg, Germany.
  • Kumar SK; Medical Department V, Amyloidosis Center, University of Heidelberg, Heidelberg, Germany.
  • Kastritis E; Medical Department V, Amyloidosis Center, University of Heidelberg, Heidelberg, Germany.
  • Dimopoulos MA; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.
  • Liedtke M; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Witteles R; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Sanchorawala V; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Szalat R; Stanford Amyloid Center, Stanford University School of Medicine, Stanford, CA.
  • Landau H; Stanford Amyloid Center, Stanford University School of Medicine, Stanford, CA.
  • Petrlik E; Section of Hematology and Oncology, Amyloidosis Center, Boston University School of Medicine, Boston Medical Center, Boston, MA.
  • Lentzsch S; Section of Hematology and Oncology, Amyloidosis Center, Boston University School of Medicine, Boston Medical Center, Boston, MA.
  • Coltoff A; Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Bladé J; Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Cibeira MT; Division of Hematology/Oncology, Columbia University Medical Center, New York, NY.
  • Cohen O; Division of Hematology/Oncology, Columbia University Medical Center, New York, NY.
  • Foard D; Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona, Spain.
  • Wechalekar A; Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona, Spain.
  • Gertz MA; National Amyloidosis Centre, University College London, Royal Free Hospital Campus, London, United Kingdom.
J Clin Oncol ; 41(7): 1393-1403, 2023 03 01.
Article em En | MEDLINE | ID: mdl-36215675
ABSTRACT

PURPOSE:

Binary cardiac response assessment using cardiac biomarkers is prognostic in light chain amyloidosis. Previous studies suggested four-level cardiac responses using N-terminal prohormone of brain natiuretic peptide improves prognostic prediction. This study was designed to validate graded cardiac response criteria using N-terminal prohormone of brain natiuretic peptide/brain natiuretic peptide. PATIENTS AND

METHODS:

This retrospective, multicenter study included patients with light chain amyloidosis who achieved at least a hematologic partial response (PR) and were evaluable for cardiac response. Four response criteria were tested on the basis of natriuretic peptide response depth cardiac complete response (CarCR), cardiac very good partial response (CarVGPR), cardiac PR (CarPR), and cardiac no response (CarNR). Response was classified as best response and at fixed time points (6, 12, and 24 months from therapy initiation). The study primary outcome was overall survival.

RESULTS:

651 patients were included. Best CarCR, CarVGPR, CarPR, and CarNR were achieved in 16%, 26.4%, 22.9%, and 34.7% of patients, respectively. Patients in cardiac stage II were more likely to achieve CarCR than patients in cardiac stage IIIA and IIIB (22% v 13.5% v 3.2%; P < .001). A deeper cardiac response was associated with a longer survival (5-year overall survival 93%, 79%, 65%, and 33% for CarCR, CarVGPR, CarPR, and CarNR, respectively; P < .001). Fixed time-point analyses and time-varying covariates Cox regression analysis, to minimize survivorship bias, affirmed the independent survival advantage of deeper cardiac responses. Four-level response performed better than two-level response as early as 12 months from therapy initiation.

CONCLUSION:

Graded cardiac response criteria allow better assessment of cardiac improvement compared with the traditional binary response system. The study re-emphasizes the importance of early diagnosis, which increases the likelihood of deep cardiac responses.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Amiloidose de Cadeia Leve de Imunoglobulina / Amiloidose Tipo de estudo: Clinical_trials / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Amiloidose de Cadeia Leve de Imunoglobulina / Amiloidose Tipo de estudo: Clinical_trials / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article